Tiziana Life Sciences (TLSA) Hits New 1-Year Low at $5.05

Tiziana Life Sciences PLC (NASDAQ:TLSA)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $5.05 and last traded at $5.10, with a volume of 2526 shares traded. The stock had previously closed at $5.95.

A number of brokerages have issued reports on TLSA. HC Wainwright restated a “buy” rating on shares of Tiziana Life Sciences in a report on Friday, December 14th. Laidlaw began coverage on Tiziana Life Sciences in a report on Monday, December 17th. They set a “buy” rating on the stock.

The firm has a market capitalization of $65.48 million and a PE ratio of -68.42.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2019/02/21/tiziana-life-sciences-tlsa-hits-new-1-year-low-at-5-05.html.

Tiziana Life Sciences Company Profile (NASDAQ:TLSA)

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.

Featured Story: Different Types of Derivatives

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit